Pulse Biosciences (PLSE) Lowered to “Sell” at BidaskClub

Pulse Biosciences (NASDAQ:PLSE) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Thursday.

Separately, ValuEngine raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday.

Shares of Pulse Biosciences (PLSE) opened at $23.06 on Thursday. Pulse Biosciences has a twelve month low of $5.82 and a twelve month high of $39.50. The stock has a market capitalization of $374.05, a price-to-earnings ratio of -16.59 and a beta of 2.40.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Tuesday, November 7th. The company reported ($0.52) earnings per share (EPS) for the quarter.

In other Pulse Biosciences news, Director Maky Zanganeh purchased 4,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was acquired at an average price of $23.07 per share, with a total value of $92,280.00. Following the acquisition, the director now directly owns 332,500 shares of the company’s stock, valued at approximately $7,670,775. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Robert W. Duggan purchased 22,901 shares of the business’s stock in a transaction on Thursday, October 19th. The shares were acquired at an average cost of $22.79 per share, with a total value of $521,913.79. Following the acquisition, the insider now directly owns 5,820,513 shares in the company, valued at $132,649,491.27. The disclosure for this purchase can be found here. Company insiders own 6.70% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Nationwide Fund Advisors bought a new position in Pulse Biosciences during the 2nd quarter worth $177,000. The Manufacturers Life Insurance Company bought a new position in Pulse Biosciences during the 2nd quarter worth $250,000. Wells Fargo & Company MN increased its position in Pulse Biosciences by 13.8% during the 3rd quarter. Wells Fargo & Company MN now owns 61,398 shares of the company’s stock worth $1,143,000 after buying an additional 7,465 shares during the period. California Public Employees Retirement System bought a new position in Pulse Biosciences during the 2nd quarter worth $297,000. Finally, OxFORD Asset Management LLP bought a new position in Pulse Biosciences during the 2nd quarter worth $310,000. Hedge funds and other institutional investors own 9.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.chaffeybreeze.com/2018/01/04/pulse-biosciences-plse-lowered-to-sell-at-bidaskclub.html.

About Pulse Biosciences

Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply